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Obesity is a major risk factor for cardiovascular disorders, including peripheral arterial disease. This review outlines the
evidence for a 6-step process for the management of obesity, starting with identifying the degree and type of obesity,
followed by target setting, life style and behavioural changes, imposed hypocaloric diet and physical activity, pharmaco-
logical treatment and consideration of eating disorders and/or bariatric surgery.
 2007 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
Keywords: Obesity; Body fat distribution; Cardiovascular risk factors; Obesity treatment.Introduction
The prevalence of obesity has increased dramatically
worldwide, about 60% in Europe in the last 15 years
and 50% in USA in the last 10 years.1e4 This increase
has a major impact on public health, because obesity
is a known risk factor for metabolic and cardiovascu-
lar diseases such as type 2 diabetes, dyslipidemia, hy-
pertension and coronary heart disease, and a major
cause of mortality. Indeed, health-care costs of obe-
sity-associated diseases increased to $ 51.6 billion in
1995, approximately 5.7% of all health-care expendi-
tures in the United States.5 An increased annual cost
of care related to increased Body Mass Index (BMI)
has also been seen. In addition, more than $ 30 billion
per year are spent on weight-reduction programs.
Unfortunately the efficacy of obesity treatments did
not increase accordingly. The standard conservative
treatments of obesity (diet, physical activity, cognitive-
behavioural therapy and drugs) are effective in the
short term, but ineffective in the long-term in 95% of
patients. A recent survey found that within one year
after diet alone approximately 75% of subjects
regained most of their weight. The addition of behav-
ioural treatments modestly improved the results.
One of a series of educational articles edited by Janet Powell, UK.
E-mail address: vittorio.giusti@chuv.ch1078–5884/000576+ 07 $32.00/0  2007 European Society for VascuHowever, even after a combined behavioural modifi-
cation and diet programme, participants regained
60% of the lost weight within 1 year.6e11 Bariatric
surgery is, actually, the only treatment that achieves a
sufficient and durable weight loss.12
The recurrent inefficacy of obesity treatments in pro-
ducing maintained weight loss is partially due to the
unrealistic expectations of patients attending an obe-
sity clinic, since these patients are often seeking a cos-
metic result.13e14 On the contrary, the target of weight
loss treatment of the World Health Organisation
(WHO), 5e10% of the initial weight, is intended to
bring about a significant reduction of cardiovascular
and metabolic risk factors and also of mortality risk.15
The evidence-basedmedical guidelines have clearly
identified the beneficial health effects of modest
weight loss, especially in patients having cardiovascu-
lar and metabolic complications. A large proportion of
obese patients with type 2 diabetes, hypertension,
dyslipidemia or coronary diseases, improves glycemic
control, reduces blood pressure, and reduces choles-
terol levels respectively, even after a weight loss of
10% or less.
The identification of overweight or obese patients
at high risk of coronary heart and/or peripheral arte-
rial disease is a primary endpoint, because the obesity
treatment can significantly reduce their risks and can
have a substantial effect on morbidity and mortality.lar Surgery. Published by Elsevier Ltd. All rights reserved.
577Management of Obesity in Patients with Peripheral Arterial DiseaseAbdominal obesity and cardiovascular diseases
Obesity is recognized as an independent risk factor
for metabolic and cardiovascular diseases. However,
patients having severe obesity can display a normal
metabolic profile with no signs of cardiovascular dis-
ease. On the contrary, any modestly overweight
patient (BMI< 30 kg/m2) can suffer from several
metabolic cardiovascular diseases irrespective of the
degree of obesity. In other words, the BMI is not the
best parameter to identify patients at risk.16e18
The risk of comorbidity development depends on
the severity of obesity, but more on body compositionand fat mass distribution. The major risk of cardiovas-
cular and metabolic diseases is linked to abdominal
repartition of fat, and chiefly to visceral localization
of adipose tissue (Fig. 1).19e20 The visceral adipocytes
are responsible for the production and secretion of
many adipokines. These hormones induce important
metabolic modifications (insulin resistance, glucose
tolerance, lipid profile) while also producing pro-
atherogenic effects (endothelial dysfunction, increase
of inflammations markers). These changes are ac-
countable for an increased risk of atherogenic dyslipi-
demia, type 2 diabetes, hypertension, atherosclerosis,
thrombosis and inflammation (Fig. 2).21e23 WaistSubcutaneous adipose tissue
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Fig. 1. This CT scan performed at the abdominal level to show the distribution of the visceral and subcutaneous adipose
tissue. There are very important differences in morphology, physiology, metabolic activity and hormonal sensitivity
between the two compartments. The visceral adipose tissue compartment has especially a metabolic role, while the abdo-
minal subcutaneous compartment has rather a function of energy store.Eur J Vasc Endovasc Surg Vol 34, November 2007
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Fig. 2. The abdominal distribution of fat mass is an independent risk factor for cardiovascular and metabolic diseases. This
risk is especially elevated when waist circumference is above 88 and 102 cm respectively in women and men.circumference is a good parameter for the evaluation
of body fat distribution and of cardiovascular and
metabolic risk factors.24
In conclusion, obesity, evaluated by BMI, and
abdominal distribution of adipose tissue, evaluated by
waist circumference, are two major risk factors for
cardiovascular and metabolic diseases.
Obesity treatments
Diet
For the last few decades, diet has been the most com-
mon treatment used to induce weight loss and it is
still frequently used. Patients seeking weight loss
have many diet options: low fat, low carbohydrate,Eur J Vasc Endovasc Surg Vol 34, November 2007high protein and low calorie. In spite of a wide use
of nutritional restriction, very few data are available
concerning effectiveness and safety of these diets in
the long-term. Prospective and randomised studies
evaluating the results of diets in the long-term are
rare. Recently, Dansinger et al., have compared the
efficacy of four types of diet during 12 months of
treatment.25 In this study the weight loss was between
2.1% and 3.2% of initial weight. Moreover, the de-
crease of weight was maximal at 2 months, followed
by a subsequent rise with an upward trend at the
end of study. Interestingly, even during the first
month the adherence to the diet was < 70% and by
6 months was < 30%. Compliance was independent
of diet type.
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Pharmacological treatment provides valid support for
management of obesity, combined with diet and/or
behavioural therapy. Drugs are retained for patients
having a BMI> 30 kg/m2 or an increased weight as-
sociated with metabolic or cardiovascular diseases.
The results of pharmacological treatment are appro-
ximately equivalent for all drug.26,27 The mean weight
loss is 6e10% of initial body weight after 1 year, with
a fast and significant decrease of weight during the
first 6 months, a subsequent rise and a final stabilisa-
tion (Table 1). If the treatment is discontinued weight
gain is common. This situation facilitates weight cy-
cling syndrome, thus increasing cardiovascular and
metabolic risk. The drug treatment should ideally be
continued and not stopped, just as all drug therapies
for chronic diseases. The aim of drug use is to contri-
bute towards a moderate weight loss in association
with long-term dietetic and behavioural measures,
with the final objective of improving metabolic and
cardiovascular profile.
Currently, only two drugs are approved by the
FDA for long-term treatment of obesity: orlistat and
sibutramine. These are recognized to be safe and
moderately effective for weight loss and reduction
of cardiovascular and metabolic risk factors. Other
drugs, with anorexiant effects (phenylpropanolamine,
fenfluramine, dexfenfluramine) are associated with
increased prevalence of cardiac valvulopathy and
risk of hemorrhagic stroke and therefore recently
have been withdrawn from the market.
Orlistat prevents the absorption of 30% of dietary
fat via inhibition of lipase activity.28 Orlistat is mini-
mally absorbed (< 1%) and so has no systemic effects.
Systematic reviews show that orlistat produces
a weight loss of 9 to 10% compared with a 4 to 6%
in placebo group.29,30 The daily dose of 120 mg three
times per day causes gastrointestinal adverse effects,
as well as increased defecation, oily evacuation, fecal
urgency, in at least 10% of patients. Nevertheless,
these effects decrease with reduction of dietary fat
intake. Orlistat also induces a significant reduction of
serum cholesterol and improves glucose tolerance,
independently of weight loss.31e34
Table 1. Pharmacological treatment consents a moderate weight
loss (5e10% initial body weight), equivalent for all drugs, enough
to reduce cardiovascular and metabolic risk factors associated
with obesity, but not sufficient to be satisfy patient expectations,
that habitually are more than 20% of initial weight
Drug Weight loss
Orlistat 6e8%
Sibutramine 7e9%
Rimonabant 7e8%Sibutramine is a serotonin and norepinephrine re-
uptake inhibitor, that acts as an appetite suppressant
and increases thermogenesis.35 The daily dose of
10 mg is effective to obtain a weight loss of 7 to 9%
when associated to behavioural therapy.36,37 This
result is short-lived if treatment is discontinued.38
Sibutramine improves also lipid profile and glucose
control, with a reduction of cardiovascular risk fac-
tors.39 The most common adverse events are increased
in blood pressure and heart rate. These effects are
dose-related and sometimes require discontinuation
of the medication.40
Fluoxetine, an antidepressant drug, also is recog-
nized for treatment of obsessive compulsive disorders,
premenstrual dysphoric disorder and especially for
eating disorders, which affect about 40% of obese
patients.41,42 Fluoxetine is unsuccessful in inducing
a significant weight loss, but it reduces compulsive
eating, therefore stopping the weight increase nor-
mally observed in patient with severe eating disorders.
Moreover, fluoxetine is the ideal antidepressant drug
for patient with an excess of body weight.
Rimonabant is a new anti-obesity drug, available in
several countries in Europe but still not approved by
FDA for treatment of metabolic syndrome. Rimona-
bant is a selective cannabinoid receptor blocker, that
reduce food intake via a modulation of dopaminergic
and opioid neurone activity.43e45 In addition, via
modulation of cannabinoid receptors in the adipo-
cytes, rimonabant should be active in a variety of
physiological processes, including regulation of
energy balance, insulin action, lipid and glucose meta-
bolism, angiogenesis.46,47 Recent studies show that
rimonabant is effective in producing a weight loss of
7e8% of initial weight after 1 year of treatment.48,49
The weight reduction is especially significant during
the first six months (as for orlistat and sibutramine).
Discontinuation of treatment induces a fast reversion
to initial weight. Rimonabant also results in signifi-
cant improvement of metabolic profile with reduction
of cardiovascular risk factors. In a recent study, 15%
of patients treated discontinued participation (7% in
placebo group). The reason for discontinuation was,
for about half of these, a psychiatric disorder.50
Bariatric surgery
Surgery has been shown to produce effective and sus-
tained weight loss, which in turn results in improve-
ment in obesity related comorbidities, quality of life
and survival.51e54 Two operations are usually pro-
posed: gastric banding and Roux-en-Y-gastric bypass
(RYGBP). Gastric banding is currently the most popu-
lar purely restrictive bariatric operation in Europe and
inmany countries. It has a low operativemorbidity, butEur J Vasc Endovasc Surg Vol 34, November 2007
580 V. Giusti• To identify degree and type of obesity
(BMI and waist circumference)
• To inform obese patient and setting
realistic weight loss goals
• To change life style: eating
behaviour and sedentary time
• To introduce hypocaloric diet and
physical activities
• To start pharmacological treatment
• To evaluate treatment of eating
disorders and /or bariatric surgery
1
2
3
4
5
6
Fig. 3. Outpatient management take in several steps in according to severity of obesity and associated comorbidities and
motivational readiness of patient. The management goals are modified and adapted in function of obtained results. A mul-
disciplinary team for management of eating disorders and/or bariatric surgery may be required.is associated with a substantial late complication rate.
RYGBP is also a restrictive procedure, but with minor
intestinal malabsorption. It provides increased weight
loss together with better food tolerance, but is asso-
ciated with nutritional deficiencies and higher opera-
tive morbidity. Some bariatric surgeons consider
Roux-en-Y gastric bypass to be the procedure of choice
in the treatment of morbid obesity. The mean weight
loss after RYGBP is 50 to 75% of excess weight two
years postoperatively. About 75% of patients maintain
this result up to four years after surgery. Importantly,
cardiovascular and metabolic comorbidities are re-
solved or improved in most patients. Bariatric surgery
imposes a rapid and drastic change in eating behaviou-
ral, bodyweight and shape perception, and inmetabolic
status, that may cause psychological and/or metabolic
imbalance. Therefore, the selection, the education and
the follow up of patients who undergo surgery, require
a multidisciplinary team in order to decrease the pre-
operative risk, the prevalence of metabolic, nutritional
and psychological complications. Currently, bariatric
surgery is limited to patient having severe obesity or
significant associated comorbidities.
Outpatient management
The first aim of obese patientmanagement is to identify
the degree and type of obesity. Two parameters are
used: BMI and waist circumference. Patients having
more than 30 kg/m2 or 25 kg/2 with a waist circumfer-
ence > 88 cm for women and 102 cm for men, have
a high cardiovascular and metabolic risk and specific
treatment to achieve weight loss is needed.Eur J Vasc Endovasc Surg Vol 34, November 2007The second step is to inform the patient of implica-
tions of excess body weight for health and then set
realistic weight loss goals. In this context, a good
physician-patient partnership is essential to achieve
and maintain weight loss.
The third step is going into action. Changes in phys-
ical activity and food intake are crucial to produce
a state of negative energy balance and obtain a weight
loss. Initially, simple modifications of daily activities
and a reduction of sedentary time can be helpful.
Moreover, effortless changes in quality and quantity
of food intake can be obtained reducing snack and
soft drink consumption, sweet and fatty food use.
When excess weight is significant and/or behav-
ioural modifications unsuccessful, the fourth step is
introducing a moderate hypocaloric diet and orga-
nized physical activities.
This fourth step can be supported by the use of
pharmacological treatment, which is the fifth phase
of obese patient management.
The following steps, concerning eating disorders
management and bariatric surgery, require a multidis-
ciplinary approach by a team of endocrinologists,
dieticians, psychiatrists and surgeons (Fig. 3).
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